Endometrioid type adenocarcinoma

Endometrioid type adenocarcinoma 

Updated: 12/21/2020

© Jun Wang, MD, PhD

General features

• Type 1 (estrogen dependent) endometrial carcinoma
• In background of endometrial hyperplasia
• Associated with estrogen replacement therapy
• More common in white

Pathogenesis

• Prolonged estrogenic stimulation with reduced progestational activity

Clinical presentations

• Asymptomatic or uterine bleeding

Pathological findings

• Crowd irregular glands, possible fusion of glands
• Atypical cells
• Squamous metaplasia: benign squamoid changes, NOT counted as solid area for FIGO
• Weak p16 reactivity (strong p16 reactivity in serous carcinoma and endocervical adenocarcinoma)

FIGO grade

• I: well differentiated, <5% nonsquamous solid component
• II: moderately differentiated, 6-50% nonsquamous solid component
• III: poorly differentiated, > 50% nonsquamous solid component
• Upgrade with marked cytological atypia

Molecular abnormality

• Loss of function of PTEN
• MSI: microsatellite instability, Lynch syndrome
• Loss of function mutations in ARID1A
• Late stage: p53

Comparison with type 2 endometrial adenocarcinoma 

Treatment

• Surgery
• Chemotherapy

Back to Adenocarcinoma of endometrium
Back to female genital tract
Back to contents